Therapeutic Efficacy of Triazavirin, a Novel Russian Chemotherapeutic, Against Influenza Virus A (H5N1)

Therapeutic activity of Triazavirin against experimental influenza A was studied on albino mice intranazally infected with influenza virus A/Chicken/Kurgan/Russia/02/05 (H5N1) vs. reference drugs (Oseltamivir, Remantadin and Arbidol®). The study showed that in a therapeutic dose of 1 mg/kg Triazavir...

Full description

Saved in:
Bibliographic Details
Main Authors: S. A. Loginova, S. V. Borisevich, V. A. Maksimov, V. P. Bondarev, S. K. Kotovskaya, V. L. Rusinov, V. N. Charushkin, O. N. Chupakhin
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2020-05-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/349
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Therapeutic activity of Triazavirin against experimental influenza A was studied on albino mice intranazally infected with influenza virus A/Chicken/Kurgan/Russia/02/05 (H5N1) vs. reference drugs (Oseltamivir, Remantadin and Arbidol®). The study showed that in a therapeutic dose of 1 mg/kg Triazavirin was efficient in protection of the animals from death. Its protective therapeutic efficacy (36.7+1.7%) was close to that of Oseltamivir (50.0+0.0%), comparable with that of Remantadin (38.3+1.7%) and higher than that of Arbidol® (11.7+1.7%). During the whole observation period (up to the terminal phase) Triazavirin inhibited the influenza virus A accumulation in the lungs of the infected albino mice by more than 3 lg.
ISSN:0235-2990